Probiodrug to Present Phase 2a Trial Results of Its Alzheimer’s Therapy PQ912 in Boston

Probiodrug to Present Phase 2a Trial Results of Its Alzheimer’s Therapy PQ912 in Boston
Probiodrug's PQ912 decreased markers of inflammation and damage in the nerve cell connections of Alzheimer's patients, according to a Phase 2a clinical trial. The company will present the results of the SAPHIR trial, which covered the therapy's safety and effectiveness, at the 10th Clinical Trials on Alzheimer's Disease Conference in Boston, Nov. 1-4. Dr. Philip Scheltens, director of the Alzheimer's Center at VU University Medical Center in Amsterdam, will discuss the findings in a presentation titled "Phase 2a study results with the glutaminylcyclase inhibitor PQ912 in early Alzheimer's Disease." He was the principal investigator of the trial. Researchers have found high levels of the glutaminylcyclase enzyme in the brains of Alzheimer's patients. PQ912 inhibits the enzyme. Preclinical-trial studies that Probiodrug did in mouse models of the disease showed that PQ912 improved the animals' cognition. The SAPHIR trial (NCT02389413) was a 12-week, double-blind, randomized, placebo-controlled trial. It  investigated PQ912's ability to treat people with early Alzheimer's disease who had never been treated before. The trial’s primary objective was to determine if PQ912 was safe, and if patients could tolerate it well. Secondary objectives included seeing it was effective against Alzheimer's, including delaying the disease's progression. One of the effectiveness yardsticks was whether PQ912 could inhibit  glutaminylcyclase enzyme production. Researchers looked at cerebrospinal fluid biomarkers of the enzyme to determine that it could. Other measures of effectiveness the team used included e
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *